Clinical management of abnormal Pap tests: differences between US and Korean guidelines
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Cervical cancer has been the most common gynecological cancer in Korea but has become a preventable disease with regular screening and proper vaccination. If regular screening is provided, cervical cancer does not progress to more than carcinoma in situ, due to its comparatively long precancerous duration (years to decades). In 2012, the American Society for Colposcopy and Cervical Pathology published guidelines to aid clinicians in managing women with abnormal Papanicolaou (Pap) tests, and they soon became the standard in the United States. Not long thereafter, the Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology published practical guidelines to reflect the specific situation in Korea. The detailed screening guidelines and management options in the case of abnormal Pap test results are sometimes the same and sometimes different in the United States and Korean guidelines. In this article, we summarize the differences between the United States and Korean guidelines in order to facilitate physicians’ proper management of abnormal Pap test results.
Abstract
Cervical cancer has been the most common gynecological cancer in Korea but has become a preventable disease with regular screening and proper vaccination. If regular screening is provided, cervical cancer does not progress to more than carcinoma in situ, due to its comparatively long precancerous duration (years to decades). In 2012, the American Society for Colposcopy and Cervical Pathology published guidelines to aid clinicians in managing women with abnormal Papanicolaou (Pap) tests, and they soon became the standard in the United States. Not long thereafter, the Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology published practical guidelines to reflect the specific situation in Korea. The detailed screening guidelines and management options in the case of abnormal Pap test results are sometimes the same and sometimes different in the United States and Korean guidelines. In this article, we summarize the differences between the United States and Korean guidelines in order to facilitate physicians’ proper management of abnormal Pap test results.
참고문헌 (30)
- Annual report of cancer statistics in Korea in 2016, "Korea Central Cancer Registry", Ministry of Health and Welfare, ~ (2018)
- 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015", Journal of Gynecologic Oncology, 30(1), pp.1~8 (2019), 대한부인종양학회[DOI]
- 임성철, "Current Status of and Perspectives on Cervical Cancer Screening in Korea", Journal of Pathology and Translational Medicine, 53(4), pp.210~216 (2019), 대한병리학회[DOI]
- Massad LS, "2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors", J Low Genit Tract Dis, 17(5Suppl 1), pp.S1~S27 (2013)
- 이재관, "Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition", Journal of Gynecologic Oncology, 24(2), pp.186~203 (2013), 대한부인종양학회
- Benard VB, "Cervical carcinoma rates among young females in the United States", Obstet Gynecol, 120, pp.1117~1123 (2012)
- Moscicki AB, "Updating the natural history of human papillomavirus and anogenital cancers", Vaccine, 30(Suppl 5), pp.F24~F33 (2012)
- Katki HA, "Five-year risks of CIN 3+and cervical cancer among women with HPV testing of ASC-US Pap results", J Low Genit Tract Dis, 17(5 Suppl 1), pp.S36~S42 (2013)
- US Preventive Services Task Force, "Screening for cervical cancer : US Preventive Services Task Force Recommendation Statement", JAMA, 320, pp.674~686 (2018)
- Lees BF, "Cervical cancer screening : evidence behind the guidelines", Am J Obstet Gynecol, 214, pp.438~443 (2016)
- Katki HA, "Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology : a population-based study in routine clinical practice", Lancet Oncol, 12, pp.663~672 (2011)
- Huh WK, "Use of primary high-risk human papillomavirus testing for cervical cancer screening : interim clinical guidance", Obstet Gynecol, 125, pp.330~337 (2015)
- Melnikow J, "Screening for cervical cancer with high-risk human papillomavirus testing : updated evidence report and systematic review for the US Preventive Services Task Force", JAMA, 320, pp.687~705 (2018)
- 민경진, "The Korean guideline for cervical cancer screening", Journal of Gynecologic Oncology, 26(3), pp.232~239 (2015), 대한부인종양학회
- Holton T, "The effect of lubricant contamination on ThinPrep(Cytyc)cervical cytology liquid-based preparations", Cytopathology, 19, pp.236~243 (2008)
- Moriarty AT, "Unsatisfactory reporting rates : 2006 practices of participants in the college of american pathologists interlaboratory comparison program in gynecologic cytology", Arch Pathol Lab Med, 133, pp.1912~1916 (2009)
- Rodríguez AC, "Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections", J Natl Cancer Inst, 100, pp.513~517 (2008)
- Katki HA, "Five-year risks of CIN 3+and cervical cancer among women with HPV-positive and HPVnegative high-grade Pap results", J Low Genit Tract Dis, 17(5Suppl 1), pp.S50~S55 (2013)
- Katki HA, "Follow-up testing after colposcopy : five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less", J Low Genit Tract Dis, 17(5 Suppl 1), pp.S69~S77 (2013)
- Massad LS, "Biopsy correlates of abnormal cervical cytology classified using the Bethesda system", Gynecol Oncol, 82, pp.516~522 (2001)
- Cox JT, "Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy", Am J Obstet Gynecol, 188, pp.1406~1412 (2003)
- Alvarez RD, "Effective cervical neoplasia detection with a novel optical detection system : a randomized trial", Gynecol Oncol, 104, pp.281~289 (2007)
- ASCUS-LSIL Traige Study(ALTS)Group, "A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations", Am J Obstet Gynecol, 188, pp.1393~1400 (2003)
- Partridge EE, "Cervical cancer screening", J Natl Compr Canc Netw, 8, pp.1358~1386 (2010)
- Vlahos G, "Conservative management of cervical intraepithelial neoplasia(CIN(2-3))in pregnant women", Gynecol Obstet Invest, 54, pp.78~81 (2002)
- Serati M, "Natural history of cervical intraepithelial neoplasia during pregnancy", Acta Obstet Gynecol Scand, 87, pp.1296~1300 (2008)
- Schorge JO, "Atypical glandular cells", Clin Obstet Gynecol, 56, pp.35~43 (2013)
- Zhao C, "Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells : results from a large academic womens hospital laboratory employing sensitive screening methods", Gynecol Oncol, 114, pp.383~389 (2009)
- Trimble CL, "Spontaneous regression of high-grade cervical dysplasia : effects of human papillomavirus type and HLA phenotype", Clin Cancer Res, 11, pp.4717~4723 (2005)
- Moscicki AB, "Regression of low-grade squamous intra-epithelial lesions in young women", Lancet, 364, pp.1678~1683 (2004)